Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: evidence for an unprecedented combination of potency and selectivity.

The Journal of Pharmacology and Experimental Therapeutics
Aron H LichtmanBenjamin F Cravatt

Abstract

Fatty acid amide hydrolase (FAAH) is the primary catabolic regulator of several bioactive lipid amides in vivo, including the endogenous cannabinoid anandamide and the sleep-inducing substance oleamide. Inhibitors of FAAH are considered a potential therapeutic approach for the treatment of several nervous system disorders, including pain, anxiety, and insomnia. However, for FAAH inhibitors to achieve clinical utility, they must not only display efficacy in vivo but also selectivity for this enzyme relative to the numerous other serine hydrolases present in mammalian proteomes. Here, we report a general strategy for evaluating the pharmacological activity and target specificity of FAAH inhibitors and its implementation to develop the first class of selective reversible inhibitors of this enzyme that are highly efficacious in vivo. Using a series of functional proteomics, analytical chemistry, and behavioral pharmacology assays, we have identified a class of alpha-keto-heterocycles that show unprecedented selectivity for FAAH relative to other mammalian hydrolases, and, when administered to rodents, raise central nervous system levels of anandamide and promote cannabinoid receptor 1-dependent analgesia in several assays of pain s...Continue Reading

References

Mar 17, 1995·The Journal of Biological Chemistry·F DesarnaudD Piomelli
Sep 1, 1993·Biochemical Pharmacology·D G Deutsch, S A Chin
Jul 31, 1998·Nature·A CalignanoD Piomelli
Oct 16, 1999·Proceedings of the National Academy of Sciences of the United States of America·J M WalkerM C Sañudo-Peña
Dec 28, 1999·Proceedings of the National Academy of Sciences of the United States of America·Y LiuB F Cravatt
May 11, 2000·Proceedings of the National Academy of Sciences of the United States of America·D L BogerB F Cravatt
Mar 10, 2001·Nature·E S LanderUNKNOWN International Human Genome Sequencing Consortium
Apr 13, 2001·Biochemistry·D KiddB F Cravatt
Jul 27, 2001·Proceedings of the National Academy of Sciences of the United States of America·B F CravattA H Lichtman
Nov 9, 2001·Nature·F Rodríguez de FonsecaD Piomelli
Apr 12, 2002·Current Medicinal Chemistry·Didier M LambertChristopher J Fowler
Apr 26, 2002·Pain·N ClaytonC T O'Shaughnessy
Jul 2, 2002·Nature Biotechnology·Gregory C AdamBenjamin F Cravatt
Jul 4, 2002·Molecular & Cellular Proteomics : MCP·Doron GreenbaumMatthew Bogyo
Dec 4, 2002·Nature Medicine·Satish KathuriaDaniele Piomelli
May 13, 2003·Nature Biotechnology·Donmienne LeungBenjamin F Cravatt
Aug 15, 2003·Proceedings of the National Academy of Sciences of the United States of America·Mohab M IbrahimT Philip Malan
Aug 28, 2003·Current Opinion in Chemical Biology·Benjamin F Cravatt, Aron H Lichtman
Sep 6, 2003·Atherosclerosis·Y Stein, O Stein
Nov 8, 2003·Trends in Molecular Medicine·Silvana GaetaniDaniele Piomelli
Nov 12, 2003·The Journal of Pharmacology and Experimental Therapeutics·Andrea G HohmannAlexandros Makriyannis
Jul 13, 2004·Proceedings of the National Academy of Sciences of the United States of America·Benjamin F CravattAron H Lichtman

❮ Previous
Next ❯

Citations

Dec 25, 2004·Psychopharmacology·S A VarvelA H Lichtman
Sep 6, 2006·Psychopharmacology·Styliani VlachouGeorge Panagis
Feb 7, 2007·Psychopharmacology·Pattipati S NaiduAron H Lichtman
Oct 13, 2010·Basic Research in Cardiology·Roisin F KellySandrine Lecour
Oct 24, 2007·Molecular Neurobiology·Christopher J Fowler
Jun 7, 2005·Pharmacology, Biochemistry, and Behavior·Christopher J FowlerStig O P Jacobsson
Jun 7, 2005·Pharmacology, Biochemistry, and Behavior·Tiziana BisognoVincenzo Di Marzo
Aug 4, 2012·ACS Chemical Neuroscience·Micah J NiphakisBenjamin F Cravatt
May 29, 2012·ACS Chemical Neuroscience·Katerina Otrubova, Dale L Boger
Aug 4, 2012·ACS Chemical Neuroscience·Tatsuya TaiNatsuo Ueda
Apr 24, 2008·Chemical Reviews·Kay AhnBenjamin F Cravatt
Jun 24, 2011·Chemical Reviews·Jonathan Z Long, Benjamin F Cravatt
Oct 26, 2006·Journal of the American Chemical Society·F Anthony RomeroDale L Boger
Dec 18, 2012·Journal of the American Chemical Society·Laura BertolacciGianpiero Garau
Apr 16, 2013·Journal of the American Chemical Society·Katerina OtrubovaDale L Boger
Jun 15, 2007·Journal of Medicinal Chemistry·Christophe HardouinDale L Boger
Jul 12, 2012·Journal of Medicinal Chemistry·Stefania ButiniMauro Maccarrone
Feb 6, 2008·Journal of Medicinal Chemistry·F Scott KimballDale L Boger
Jul 18, 2008·Journal of Medicinal Chemistry·Joie GarfunkleDale L Boger
Nov 26, 2008·Nature Chemical Biology·Jonathan Z LongBenjamin F Cravatt
Dec 18, 2008·Nature Chemical Biology·Lawrence J Marnett
Aug 24, 2010·Nature Neuroscience·Joel E SchlosburgBenjamin F Cravatt
Nov 22, 2011·Nature Neuroscience·Jin FuDaniele Piomelli
Apr 2, 2010·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Katherine W FalenskiLaura J Sim-Selley
May 1, 2008·Nature Reviews. Drug Discovery·Vincenzo Di Marzo
Jan 4, 2012·Nature Reviews. Drug Discovery·Daniel A Bachovchin, Benjamin F Cravatt
Mar 31, 2012·Nature Reviews. Drug Discovery·Bernard P RoquesMichel Wurm
Mar 17, 2006·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Marco BortolatoDaniele Piomelli
Aug 30, 2008·Proceedings of the National Academy of Sciences of the United States of America·Mauro MileniRaymond C Stevens
Nov 18, 2009·Proceedings of the National Academy of Sciences of the United States of America·Jonathan Z LongBenjamin F Cravatt
Apr 20, 2011·Proceedings of the National Academy of Sciences of the United States of America·Xiaoshan MinZhulun Wang
May 31, 2008·British Journal of Anaesthesia·A Dray
Jan 1, 2011·ILAR Journal·Divya RameshAron H Lichtman
Mar 14, 2007·Current Opinion in Lipidology·Vincenzo Di Marzo, Stefania Petrosino
Oct 31, 2012·Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences·Katarzyna Starowicz, Barbara Przewlocka
May 3, 2008·The Journal of Pharmacology and Experimental Therapeutics·Lisa L MerrittM Imad Damaj
Jan 2, 2009·The Journal of Pharmacology and Experimental Therapeutics·Pattipati S NaiduAron H Lichtman
Jan 27, 2009·The Journal of Pharmacology and Experimental Therapeutics·Joel E SchlosburgAron H Lichtman
Jun 9, 2009·The Journal of Pharmacology and Experimental Therapeutics·S G KinseyA H Lichtman

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.